

## **STUDY OF CASES OF THYROID DISORDER HYPERTHYROIDISM AND HYPOTHYROIDISM**

**AUHOOD KADHIM ZAID**

Department of Chemistry, College of Science, University of Thi-Qar, Iraq

### **ABSTRACT**

This study included the to identify the two cases thyroid disorders by measuring the levels of thyroid hormones. The study included three groups, the first group (I) included 20 healthy volunteers were taken as a standard (control group), second group (II) 30 patients with hyperthyroidism , the third group (III) 30 patients with hypothyroidism. The results showed the presence of a significant increase( $p < 0.01$ ) in the levels of triiodothyronine (T3) and Thyroxine

The current study included a study of thyroid disorders by measuring thyroid hormones triiodothyronine (T3), Thyroxine (T4) and thyroid stimulating hormone (TSH).

## MATERIALS AND METHODS

### Selection of Subjects

This study was carried on 20 donor healthy and 30 patients in the center of Diabetic and Endocrine Gland specialization in Thi-Qar governorate, Iraq. They are classified into three groups:-

**Group I:** control group included 20 donor healthy with ages ranged between 20 and 50 years old, with no previous diseases which may interfere with parameters analyzed in this study.

**Group II:** This group involved 30 patients they have been previously diagnosed hyperthyroidism by the doctor.

**Group III:** Included 30 patients they have been previously diagnosed hypothyroidism by the doctor.

### Hormone Analysis

About (3 mL) of blood samples of patients with hyperthyroidism and hypothyroidism and controls were taken and allowed to clot to get serum by putting it in empty disposable tube's centrifuge to separate it in the centrifuge at 3000 rotor per minute (*rpm*) for 10 min, the serum samples were separated, stored at (-20°C) for later measurement biochemical parameters, unless used immediately.

Thyroxine (T4), triiodothyronine (T3) and thyroid stimulating hormone (TSH) is an automated quantitative test (Vidas company, France) for use on the VIDAS instruments, for the enzyme immunoassay determination of human T4, T3 and TSH in human serum or plasma (lithium heparin ate) using enzyme linked fluorescent assay (ELFA) technique (Beckers, 1982; Helfand and Crapo, 1990; Biersack and Hotze, 1991; Wondisford *et al*, 1996).

### Statistical Analysis

The data were analyzed using **SPSS** version 10.0, the results were expressed as mean  $\pm$  standard deviations (mean  $\pm$  SD). One way ANOVA-test was used to compare parameters in different studied groups. P-values ( $P \leq 0.01$ ) were considered statistically significant. (Sabine and Brian, 2004).

## RESULTS

Table 1 showed a significant increase ( $p < 0.01$ ) in levels of triiodothyronine (T3) and thyroxine (T4) hormones in patients with hyperthyroidism (group II) compared with control group (group I), While, the results recorded a significant decrease ( $p < 0.01$ ) in levels of triiodothyronine (T3) and thyroxine (T4) hormones in patients with hypothyroidism (group III) compared with group (I), Also, there was a significant decrease ( $p < 0.01$ ) in level of thyroid-stimulating hormone (TSH) in patients with hyperthyroidism (group II) compared with control group (group I), While, the results recorded a significant increase ( $p < 0.01$ ) in level of thyroid-stimulating hormone (TSH) in patients with hypothyroidism (group III) compared with group (I). The results indicated a significant decrease ( $p < 0.01$ ) in levels of triiodothyronine (T3) and thyroxine (T4) hormones in patients with hypothyroidism (group III) compared with group (II), While, the results recorded a significant increase ( $p < 0.01$ ) in level of thyroid-stimulating hormone (TSH) in patients with hypothyroidism (group III) compared with group (II).

**Table 1: T3, T4 and TSH Hormones Levels (Nmol/L) of Groups**

Treatments	n	T3 Level (nmol/l)	T4 level (nmol/l)	TSH Level (nmol/l)
Group I	20	3.03±0.27 <sup>b</sup>	101.45±13.49 <sup>b</sup>	2.82±1.27 <sup>b</sup>
Group II	30	5.26±1.14 <sup>a</sup>	194.08±47.63 <sup>a</sup>	0.212±0.216 <sup>c</sup>
Group III	30	0.99±0.70 <sup>c</sup>	37.76±14.11 <sup>c</sup>	4.402±1.954 <sup>a</sup>

N: Number of subjects

## DISCUSSIONS

Thyroid dysfunctions that occur in pregnant and postpartum women, during fetal development, and in childhood are caused by the abnormal secretion of thyroid hormones. The medical conditions include hyperthyroidism and hypothyroidism (Woeber, 2000). The causes of hypothyroidism were varied, usually caused by dietary lack, but sometimes caused by improper assimilation, radioactive iodine that causes follicle destruction, surgery and pharmacological agents (Vanderpump *et al*, 1995; Singer *et al*, 1995).

Laboratory testing of thyroid stimulating hormone levels in the blood is considered the best initial test for hypothyroidism; a second TSH level is often obtained several weeks later for confirmation. Levels may be abnormal in the context of other illnesses, and TSH testing in hospitalized people is discouraged unless thyroid dysfunction is strongly suspected

(Cobin *et al*, 2012; Pearce, 2012) An elevated TSH level indicates that the thyroid gland is not producing enough thyroid hormone, and free T4 levels are then often obtained. Measuring T3 is discouraged in the assessment for hypothyroidism. Many cases of hypothyroidism are associated with mild elevations in creatine kinase and liver enzymes in the blood. They typically return to normal when hypothyroidism has been fully treated. Levels of cholesterol, low-density lipoprotein and lipoprotein (a) can be elevated; the impact of subclinical hypothyroidism on lipid parameters is less well-defined (MacIsaac and Grossmann, 2012; Klubo-Gwiedzinska and Wartofsky, 2012).

Hyperthyroidism, often called overactive thyroid and sometimes hyperthyreosis, is a condition in which the thyroid gland produces and secretes excessive amounts of the free (not protein bound circulating in the blood) thyroid hormones triiodothyronine (T3) and/or thyroxine (T4). (Biondi and Cooper, 2008).

Measuring the level of thyroid-stimulating hormone (TSH), produced by the pituitary gland (which in turn is also regulated by the hypothalamus's TSH Releasing Hormone) in the blood is typically the initial test for suspected hyperthyroidism. A low TSH level typically indicates that the pituitary gland is being inhibited or "instructed" by the brain to cut back on stimulating the thyroid gland, having sensed increased levels of T<sub>4</sub> and T<sub>3</sub> in the blood. In rare circumstances, a low TSH indicates primary failure of the pituitary, or temporary inhibition of the pituitary due to another illness (euthyroid sick syndrome) and so checking the T<sub>4</sub> and T<sub>3</sub> is still clinically useful.

Measuring specific antibodies, such as anti-TSH-receptor antibodies in Graves' disease, or anti-thyroid-peroxidase in Hashimoto's thyroiditis a common cause of hypothyroidism may also contribute to the diagnosis.

The diagnosis of hyperthyroidism is confirmed by blood tests that show a decreased thyroid-stimulating hormone (TSH) level and elevated T4 and T3 levels. TSH is a hormone made by the pituitary gland in the brain that tells the thyroid gland how much hormone to make. When there is too much thyroid hormone, the TSH will be low.

(Geffner and Hershman, 1992; Hall, 1994).

## CONCLUSIONS

Results indicated a relationship thyroid disorders with levels of thyroid hormones. Hyperthyroidism is characterized by a high level of T3, T4 and low level TSH hormones. While hypothyroidism is characterized by low level of T3, T4 and high level TSH hormones.

## REFERENCES

1. Cobin, J. R.; Gharib, R. H.; Hennessey, H.; Klein J. V, Mechanick, I; Pessah-Pollack, J.I.; Singer, R.; Woeber, P. A.; KA for the American Association of Clinical Endocrinologists and the American Thyroid Association Taskforce on Hypothyroidism in Adults."Clinical Practice Guidelines for Hypothyroidism in Adults". *Thyroid* **22** (12): 1200–1235. (2012)
2. MacIsaac, R.J.; Grossmann, M. "Hypothyroidism". *Australian Family Physician* **41** (8): 556–62 (2012).
3. Geffner, D. L; Hershman J. M. " $\beta$ -Adrenergic blockade for the treatment of hyperthyroidism". *The American Journal of Medicine* **93** (1): 61–8(1992).
4. Klubo-Gwiedzinska, J; Wartofsky, L. "Thyroid emergencies". *Medical Clinics of North America* **96** (2): 385–403(2012).
5. Pearce, E.N. "Update in lipid alterations in subclinical hypothyroidism". *The Journal of Clinical endocrinology and Metabolism* **97** (2): 326–33(2012).
6. Arthur, C.G. and John, E.H. *Text book of medical physiology*; Elsevier Saunders; Eleventh Edition; p.p.1116 (2006).
7. Beckers, C. *Thyroid hormone synthesis and circulating thyroid hormones in thyroid diseases*, world federation of nuclear medicine and biology; pergamon press;1-21 (1982).
8. Biersack, H.J. and Hotze, A. *The clinican and the thyroid*; *Eur.J.Nucl.Med.*; 18: 761-778 (1991).
9. Biondi B.; Cooper, D.S. "The clinical significance of subclinical thyroid dysfunction".*Endocrine Reviews* **29** (1): 76–131(2008).
10. Birte, N. *Hyperthyroidism (primary)*; *Clinical Evidence*; 07: 611 (2010).
11. Burtis, C. A.; Edward, R. A. and David, E. B. *Tietz text book of clinical chemistry and molecular diagnostics*, Elsevier Saunders (2006).
12. Hall, R. *Hyperthyroidism and Grave's disease*. In: Besser, G.M.; Thorner, M.O.;eds. *Clinical endocrinology*. 2<sup>nd</sup> ed. London: Mosby Wolfe; 1-24 (1994).
13. Harjai, K.J.and Licata, A.A. *Effects of amiodarone on thyroid function*. *Ann. Intern.Med.*; 126(1):63-73 (1997).
14. Helfand, M.; Crapo, L.M. *Screening for thyroid disease*. *Annals for thyroid disease*. *Annals of Internal Medicine*; 112(11):840-849 (1990).

15. Klein, I. Thyroid hormone and the cardiovascular system. *Am. J. Med.*; 88: 631-7 (1990).
16. Larsen, P.R.; Davies, T.F. and Hay, I.D. The thyroid. In William R.H.; Wilson, J. D.; Foster, D. W, Kronenberg, H.M, eds. *William textbook of endocrinology*. 9<sup>th</sup> ed. Philadelphia:saunders;389-416 (1998).
17. Little, J.W.; Falace, D.A.; Miller, C.S. and Rhodus, N.L. Thyroid disease. In: Little, J.W.; ed. *Dental management of the medically compromised patient*. 5<sup>th</sup> ed. St.Louis: Mosby; 419-33 (1997).
18. Poumpros, E.; Loberg, E. and Engstrom, C. Thyroid function and root resorption. *Angle Orthod*; 64: 389-94 (1994).
19. Sabine, L and Brian, S. E.; *A handbook of statistical analyses using SPPSS 11*; Chapman and hall/CRC press LLC, 339(2004).
20. Singer, P. A; Cooper, D. S. and Levy, E. G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. *J. A. M. A.*; 273:808-12 (1995).
21. Tariq, M. K; Saqib, M. and Inayat, U.D. Correlation between plasma thyroid hormones and liver enzymes level in thyrotoxic cases and controls in Hazara division; *J.Ayub.Med.Coll.Abbottabad*;22(2) (2010).
22. Vanderpump, M. P; Turnbridge, W. M. and French, J. M.; et al. The incidence of thyroid disorders in the community: a 20 year follow up of the wickham survey. *Clin Endocrinol*; 43(1):55-68 (1995).
23. Wendy, A. *Clinical chemistry alaboratory perspective*; F.A.DAVIS Company. Philadelphia; p.p. 605 (2007).
24. Woeber, K. A. Update on the management of hyperthyroidism and hypothyroidism. *Arch. Fam. Med.*; 9: 743-7 (2000).
25. Wondisford, F. E; Magner, J. A. and Weintraub, B. D. Chemistry and biosynthesis of thyrotropin. In: Braverman, L. E. and Utiger, R. D. eds. *Werner and Ingbar's. The thyroid*. 7<sup>th</sup> ed. Philadelphia; Lippincott-Raven; 190-207 (1996).

